abrocitinib abrocitinib abrocitinib, sold under the brand name cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). it is a janus kinase inhibitor and it was developed by pfizer. it is taken by mouth. abrocitinibclinical datatrade namescibinqoother namespf-04965842ahfs/drugs.commonographlicense data eu ema: by inn us dailymed: abrocitinib routes ofadministrationby mouthdrug classjanus kinase inhibitoratc coded11ah08 (who) legal statuslegal status ca: ℞-only us: ℞-only eu: rx-only pharmacokinetic dataelimination half-life2.8–5.2 hexcretion1.0–4.4% unchanged in urineidentifierscas number1622902-68-4pubchem cid78323835drugbankdb14973 ychemspider68006894 yunii73sm5sf3orkeggd11400 nchemblchembl3655081echa infocard100.251.498 chemical and physical dataformulac14h21n5o2smolar mass323.42 g·mol−13d model (jsmol)interactive image smiles cccs(=o)(=o)nc1cc(n(c)c2ncnc3ccc23)c1 inchi inchi=1s/c14h21n5o2s/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18h,3,6-8h2,1-2h3,(h,15,16,17)/t10-,11+ ykey:iuewxnhskrwhdy-phimtyicsa-n y the most common side effects include nausea (feeling sick), headache, acne, herpes simplex (viral infection of the mouth or the genitals), increased levels of creatine phosphokinase in the blood (an enzyme released into the blood when muscle is damaged), vomiting, dizziness and pain in the upper belly. abrocitinib was approved for medical use in the european union in december 2021, and in the united states in january 2022. medical uses in the eu, abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. in the us, abrocitinib is indicated for the treatment of people twelve years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. side effects the most common adverse effects in studies were upper respiratory tract infection, headache, nausea, and diarrhea. pharmacology mechanism of action it is a selective inhibitor of the enzyme janus kinase 1 (jak1). pharmacokinetics abrocitinib is quickly absorbed from the gut and generally reaches highest blood plasma concentrations within one hour. only 1.0 to 4.4% of the dose are found unmetabolized in the urine. history april 2016: initiation of phase 2b trial december 2017: initiation of jade mono-1 phase 3 trial may 2018: results of phase 2b trial posted october 2019: results of phase 3 trial presented june 2020: results of second phase 3 trial published society and culture legal status in october 2021, the committee for medicinal products for human use (chmp) of the european medicines agency (ema) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product cibinqo, intended for the treatment of atopic dermatitis. the applicant for this medicinal product is pfizer europe ma eeig. in december 2021, the european commission approved abrocitinib for the treatment of atopic dermatitis. in january 2022, the us food and drug administration (fda) approved abrocitinib for adults with moderate-to-severe atopic dermatitis.